NXGLW · NEXGEL, Inc.

The appointment of Ian Blackman as CFO represents a high-materiality leadership transition for NEXGEL, occurring at a pivotal strategic inflection point — the planned integration of Celularity’s regenerative biomaterial portfolio. Blackman brings deep expertise in scaling businesses, managing complex M&A transactions, and strengthening financial infrastructure across luxury consumer and healthcare-adjacent sectors, including prior roles at McIntosh Group, Diptyque, Byredo, and Universal Music Group. His compensation package reflects both immediate accountability and long-term alignment: the $250,000 base salary is standard for mid-cap biotech/consumer health firms, while the EBITDA-linked 2026 bonus directly ties his near-term incentive to execution against defined financial milestones. The 160,000-option grant — with front-loaded and extended vesting — balances retention with performance discipline, and the tiered severance structure provides escalating protection that mirrors typical market practice for newly appointed C-suite officers. Critically, the press release explicitly positions Blackman’s role as instrumental in guiding the Celularity transaction process and integration planning, suggesting his mandate extends beyond traditional finance stewardship to include strategic capital allocation and operational synergy realization. His background in high-growth consumer markets and prior success driving >90% organic revenue growth and >335% EBITDA expansion at McIntosh Group signals investor-relevant capability in commercial scaling — a key need as NEXGEL expands its branded consumer and healthcare partnerships alongside its contract manufacturing business.